These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19950409)

  • 21. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
    Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
    Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple clinical vertebral fractures following denosumab discontinuation.
    Anastasilakis AD; Makras P
    Osteoporos Int; 2016 May; 27(5):1929-30. PubMed ID: 26694593
    [No Abstract]   [Full Text] [Related]  

  • 23. Denosumab--a new option in the treatment of osteoporosis.
    Franek E
    Endokrynol Pol; 2011; 62(1):79-83. PubMed ID: 21365584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing options for the treatment of osteoporosis.
    Khosla S
    N Engl J Med; 2009 Aug; 361(8):818-20. PubMed ID: 19671654
    [No Abstract]   [Full Text] [Related]  

  • 26. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 27. Ask the doctor. I'm looking for information on Prolia and Reclast as alternatives to Boniva.
    Robb-Nicholson C
    Harv Womens Health Watch; 2011 Nov; 19(3):8. PubMed ID: 22276325
    [No Abstract]   [Full Text] [Related]  

  • 28. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
    Johnson GL
    Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
    von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
    Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB; Pathak R
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug-induced osteoporosis].
    Tanaka Y
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():394-8. PubMed ID: 18074570
    [No Abstract]   [Full Text] [Related]  

  • 33. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone targeted therapy in breast cancer: present and future.
    Huober J; Thürlimann B
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
    [No Abstract]   [Full Text] [Related]  

  • 35. Denosumab for the prevention of osteoporotic fractures in postmenopausal women.
    Waugh N; Royle P; Scotland G; Henderson R; Hollick R; McNamee P
    Health Technol Assess; 2011 May; 15 Suppl 1():51-9. PubMed ID: 21609653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
    Törring O
    Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
    [No Abstract]   [Full Text] [Related]  

  • 37. A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
    Vignot S; Khayat D
    J Clin Oncol; 2009 Apr; 27(10):1534-6. PubMed ID: 19237628
    [No Abstract]   [Full Text] [Related]  

  • 38. The role and efficacy of denosumab in the treatment of osteoporosis: an update.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Mar; 10(2):205-17. PubMed ID: 21208140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of osteoporosis in an active female patient?].
    Fassbender WJ
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2416. PubMed ID: 18988136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.